Skip to main content
AAO-HNSF 2024 Annual Meeting & OTO EXPO Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Expert Lectures

Head and Neck Surgery

Cutaneous Melanoma: 2024 Management Pearls in the Immunotherapy Era

Saturday, September 28, 2024
4:00 PM – 5:00 PM EDT
Location: MBCC, 209
CME/MOC Credit: 1
Disclosure(s):
Cecelia E. Schmalbach, MD, MSc:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Carol R. Bradford, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

PROGRAM DESCRIPTION: The management of cutaneous head and neck melanoma experienced transformational change over the past several years. This Expert Series provides a contemporary, case-based concise framework to highlight these changes. The work-up and treatment options for our melanoma patients will be reviewed in an evidence based fashion. Sentinel node biopsy techniques and pearls will be shared along with the utility of a completion neck dissection in the context of the MSLT-II trial. New advances in targeted therapy to include PD-1 inhibitors and associated clinical trials will be reviewed so that physicians can hold meaningful patient conversations regarding both neoadjuvant and adjuvant treatment options. We will highlight the important changes and associated challenges we face in managing our complex melanoma patients. Participants will leave this 1 hour course with a clear understanding of 2024 standard of care for cutaneous head and neck melanoma

Learning Objectives:

  1. List 2024 evidence-based melanoma guidelines for work-up & staging to include radiographic imaging and sentinel node biopsy.
  2. Define the utility of a completion neck dissection in the setting of a positive sentinel node given MSLT-II trial results and advances in immunotherapy.
  3. Formulate a plan to educate patients on melanoma adjuvant and neoadjuvant therapy options to include novel targeted agents such as PD-1 inhibitors.

    Lead Presenter(s)

  • Cecelia E. Schmalbach, MD, MSc

    The David Myers, MD Professor and Chair, Department of Otolaryngology – Head & Neck Surgery
    Temple University
    Philadelphia, Pennsylvania, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

    • Co-Presenter(s)

  • CB

    Carol R. Bradford, MD

    Dean and Professor of Otolaryngology-Head and Neck Surgery
    The Ohio State University College of Medicine
    Columbus, OH, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.